Hematopoietic Stem Cell Capture and Directional Differentiation into Vascular Endothelial Cells for Metal Stent-Coated Chitosan/Hyaluronic Acid Loading CD133 Antibody

Abstract

A series of metal stents coated with chitosan/hyaluronic acid (CS/HA) loading antibodies by electrostatic selfassembled method were prepared, and the types of cells captured by antibodies and their differentiation in vascular endothelial cells (ECs) evaluated by molecular biology and scanning electron microscope. The results showed that CD133 stent can selectively capture hematopoietic stem cells (HSC),which directionally differentiate into vascular ECs in peripheral blood by (CS/HA) induction, and simultaneously inhibit migration and proliferation of immune cells and vascular smooth muscle cells (MCs). CD34 stent can capture HSC, hematopoietic progenitor cells that differentiate into vascular ECs and immune cells, promoting smooth MCs growth, leading to thrombosis, inflammation, and rejection. CD133 stent can be implanted into miniature pig heart coronary and can repair vascular damage by capturing own HSC, thus contributing to the rapid natural vascular repair, avoiding inflammation and rejection, thrombosis and restenosis. These studies demonstrated that CD133 stent of HSC capture will be an ideal coated metal stent providing a new therapeutic approach for cardiovascular and cerebrovascular disease.

Strategies to develop endogenous stem cell-recruiting bioactive materials for tissue repair and regeneration

“…Alternatively, the same antibody can be loaded and linked on the surface of stainless steel stents using chitosan/hyaluronic acid (CS/HA) multilayers that can be assembled through electrostatic interactions (Figure 5D) [128]. These stents selectively captured HSCs since the CD133 marker is expressed only on HSCs.…”

Chitosan as Functional Biomaterial for Designing Delivery Systems in Cardiac Therapies

“…Chitosan-based hydrogels are most widely used for cell delivery applications. Other forms of chitosan that are used for cell delivery applications include microcapsules [ 36 ], coatings [ 37 ], nanofibrous scaffolds/patches [ 38 ], and recently 3D-printed structures [ 39 ]. Table 1 gives an exhaustive review of chitosan-based materials for cell therapy applications.…”

Antibody CD133 Biofunctionalization of Ammonium Acryloyldimethyltaurate and Vinylpyrrolidone Co-Polymer-Based Coating of the Vascular Implants

“…Another approach to stents biofunctionalization is to cover its surface with bionanocomposite with immobilized biomolecules designed to capture endothelial progenitor cells [ 2 , 23 ]. Once captured EPCs differentiate into a mature endothelium, thus increasing stents biocompatibility [ 4 , 5 , 7 , 24 ]. One of the approaches was to use immobilization of anti-CD34 antibodies, for biofunctionalization of stent, but such surface tends to have insufficient biocompatibility.…”

“…Therefore, attracting EPCs emerged as alternative strategy. Use of EPCs specific anti-CD133 coated surface has been shown to have high reendothelialization rate, when used in stents [ 23 , 24 ].…”